Ceftolozane

Summary

Ceftolozane (CHEMBL2103872) is an approved small molecule; indicated across 7 conditions including pneumonia and pyelonephritis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 7 conditions
• Clinical trials: 32
• Chemistry: 666.7 Da · C23H30N12O8S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2103872
Name	Ceftolozane
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	71457955
ChEBI	CHEBI:134719
Molecular formula	C23H30N12O8S2
Molecular weight	666.7
InChIKey	JHFNIHVVXRKLEF-DCZLAGFPSA-N

SMILES: CC(C)(C(=O)[O-])O/N=C(/C1=NSC(=N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC(=C(N4C)N)NC(=O)NCCN)C(=O)O

IUPAC name: 2-[(Z)-[2-[[(6R,7R)-3-[[5-amino-4-(2-aminoethylcarbamoylamino)-1-methylpyrazol-2-ium-2-yl]methyl]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-yl]amino]-1-(5-amino-1,2,4-thiadiazol-3-yl)-2-oxoethylidene]amino]oxy-2-methylpropanoate

ChEBI definition: A fifth-generation cephalosporin antibiotic having (5-amino-4-{[(2-aminoethyl)carbamoyl]amino}-1-methyl-1H-pyrazol-2-ium-2-yl)methyl and [(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino side groups located at positions 3 and 7 respectively; developed for the treatment of infections with gram-negative bacteria that have become resistant to conventional antibiotics.

Also known as: Ceftolozane, Ceftolozano, CXA-101, CXA-101 FREE BASE, FR-264205, cephalosporin, CEFTOLOZANE

Parent form; salt/anhydrous children: CHEMBL1213250

Patent coverage: 402 distinct patent families (951 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 856 (90%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
pneumonia	3	MONDO:0005249	EFO:0003106
pyelonephritis	3	MONDO:0006939	EFO:1001141
lung disorder	3	MONDO:0005275	EFO:0003818
urinary tract infection	2	MONDO:0100338	EFO:0003103
infectious disease	2	MONDO:0005550	EFO:0005741

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 32.

Phase distribution

Phase	Trials
Not specified	9
PHASE4	8
PHASE2	5
PHASE1	5
PHASE3	4
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02421120	PHASE4	COMPLETED	Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients
NCT02913118	PHASE4	UNKNOWN	Adjunctive Therapy of Andrographolid Sulfonatein Community Acquired Pneumonia
NCT03002506	PHASE4	TERMINATED	Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Burns
NCT04062175	PHASE4	COMPLETED	Efficacy of Adding Azithromycin to Cephalosporin Before Cesarean Delivery
NCT04401553	PHASE4	WITHDRAWN	Prophylactic Antibiotics for Surgical Site Infections and Beta-Lactam Allergy
NCT04673175	PHASE4	TERMINATED	Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation
NCT05094154	PHASE4	COMPLETED	Effect of Antibiotic Choice On ReNal Outcomes (ACORN)
NCT06035055	PHASE4	UNKNOWN	Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and Bronchiectasis
NCT01853982	PHASE3	TERMINATED	Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia
NCT02070757	PHASE3	COMPLETED	Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)
NCT03830333	PHASE3	COMPLETED	Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)
NCT05267977	PHASE3	WITHDRAWN	Antibiotic Use & Open Fracture of the Lower Extremity
NCT00921024	PHASE2	COMPLETED	Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections
NCT01147640	PHASE2	COMPLETED	Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections
NCT03217136	PHASE2	COMPLETED	MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)
NCT03230838	PHASE2	COMPLETED	MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)
NCT03309657	PHASE1/PHASE2	COMPLETED	Pharmacokinetics of Ceftolozane/Tazobactam in Plasma and Cerebrospinal Fluid
NCT03485950	PHASE2	COMPLETED	Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam
NCT02266706	PHASE1	COMPLETED	Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010)
NCT02387372	PHASE1	COMPLETED	Plasma Pharmacokinetics (PK) & Lung Penetration of Ceftolozane/Tazobactam in Participants With Pneumonia (MK-7625A-007)
NCT02508753	PHASE1	COMPLETED	Safety Study Designed to Study the Effects of Two Different Doses of CXA-101/Tazobactam, a Low Dose and a High Dose, on the QT/QTc Intervals in Healthy Subjects
NCT02620774	PHASE1	COMPLETED	Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections
NCT04223752	PHASE1	COMPLETED	Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036)
NCT06422533	Not specified	RECRUITING	Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients
NCT07442357	Not specified	NOT_YET_RECRUITING	The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial
NCT01750385	Not specified	UNKNOWN	Bacteremia and Procalcitonin Levels in Peroral Endoscopic Myotomy for Achalasia
NCT02314013	Not specified	UNKNOWN	Randomized Clinical Trial for the Uncomplicated Diverticulitis in Right Colon
NCT02490293	Not specified	COMPLETED	Is it Fair to Use Antibiotics After Laparoscopic Cholecystectomy for the Patients With Acutely Inflamed Gallbladder?
NCT03917134	Not specified	UNKNOWN	Prevention of Vaginal Cellulitis or Vaginal Cuff Abscess After Laparoscopic Hysterectomy
NCT04196608	Not specified	UNKNOWN	In Vitro Activity of Ceftolozane/Tazobactam and Imipenem/Relebactam in Clinical Isolates of Pseudomonas Aeruginosa and Enterobacterales Collected From Hematology and Oncology Patients
NCT04257812	Not specified	UNKNOWN	Monitoring of Ceftolozane-Tazobactam Plasmatic Levels in Critical Patients
NCT04352855	Not specified	UNKNOWN	Ceftolozane-tazobactam for the Treatment of Respiratory Infections Due to Extensively Drug-resistant Pseudomonas Aeruginosa Among Critically Ill Patients: a Retrospective Study.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).